Blue Water Acquisition III - Unit. (BLUWU) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Blue Water Acquisition III - Unit. (BLUWU) has outperformed Tenaya Therapeutics (TNYA) over the past year, gaining 4.7% versus a loss of 70.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLUWU | TNYA |
|---|---|---|
| Share price | $10.50 | $0.5529 |
| Market cap | — | $123.98M |
| 1-day change | 0.00% | +1.59% |
| YTD return | -0.47% | -23.57% |
| 1-year return | +4.69% | -70.26% |
| 5-year return | — | -97.35% |
| EPS (TTM) | — | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.85 | $2.35 |
| 52-week low | $10.03 | $0.521 |
| Distance from 52-week high | -18.29% | -76.47% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +478.77% |
| Average volume | 48 | 2.27M |
| Shares outstanding | — | 224.23M |
| Employees | — | 70 |
| Sector | Financial Services | Health Care |
| Industry | Shell Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLUWU has outperformed TNYA by 74.9 percentage points over the past year.
- The two companies sit in different sectors: Blue Water Acquisition III - Unit. in Financial Services and Tenaya Therapeutics in Health Care.
About Blue Water Acquisition III - Unit.
BLUWU stock →Blue Water Acquisition Corp. III does not have significant operations.
Financial Services · Shell Companies
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
BLUWU vs TNYA FAQ
Which stock has performed better over the past year, BLUWU or TNYA?
BLUWU returned +4.69% over the past 12 months, compared with -70.26% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Blue Water Acquisition III - Unit. and Tenaya Therapeutics in the same industry?
No. Blue Water Acquisition III - Unit. is in the Financial Services sector, while Tenaya Therapeutics is in Health Care.